Is Edgewise Therapeutics, Inc. (EWTX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
From Yahoo Finance: 2025-05-05 07:57:00
In a recent article, we listed the Top 11 Small Cap Stocks to Buy with the Biggest Upside Potential. Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is being compared against other top small cap stocks for potential growth.
Jill Carey Hall, BofA Securities head of U.S. small/mid-cap strategy, discussed the impact of tariffs on small caps and the importance of earnings recovery for the sector. Uncertainty remains high despite potential good news on tariffs.
Hall highlighted the need for selectivity in small cap investments, focusing on high-quality domestic stocks with strong margins. She emphasized the importance of monitoring corporate commentary as small-cap reporting kicks off this earnings season.
Edgewise Therapeutics, Inc. (EWTX) ranks seventh on the list of top small-cap stocks with the biggest analyst upside potential. The company develops innovative treatments for rare muscle disorders and severe cardiac conditions, with its lead product candidate in late-stage clinical trials.
Guggenheim analyst Debjit Chattopadhyay initiated coverage of Edgewise Therapeutics, Inc. (EWTX) with a Buy rating and $41 price target due to the company’s promising small molecules in mid-late stage clinical development. The enterprise value offers a compelling entry point for investors.
While EWTX shows potential as an investment, there are AI stocks with greater promise for higher returns in a shorter time frame. Consider exploring other AI stocks with significant upside potential for a more promising investment opportunity.